Microbot Medical - FloodGate Medical

A Mission to Create Access-Ability for All

About Us

Our company was founded by thought leaders in surgical robotics with a proven track record of building companies. Their vision is to pave the way to the next generation of surgical robotics by transforming robots from large pieces of capital equipment to accessible, single-use robotic systems. The LIBERTY Robotic System is the first iteration of our goal to re-think how robotic systems can change health care, but we continue to stay focused on how the ecosystem around robotics can be re-imagined and evolve.

Look at the Leaders of Microbot Medical

Harel Gadot

CEO, President and Chairman

Simon Sharon

GM, Chief Technology Officer

Paul Mullen

Vice President Sales

Featured Innovations

LIBERTY

LIBERTY is the first ever single-use endovascular surgical robotic system designed to streamline endovascular procedures.

*LIBERTY is still under development and is not currently available for sale in the USA or any other jurisdiction

News and Stories

Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers

HINGHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the addition of two senior officers that round out the Company’s U.S. commercial leadership team. Combined with the recent addition of Paul Mullen as Vice President of Sales, the Company is preparing for U.S. commercial launch in advance of the expected U.S. Food and Drug Administration’s (FDA) decision in the second quarter of 2025.

Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System

HINGHAM, Mass., April 09, 2025 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting. The study was performed at three leading medical centers in the U.S.; Memorial Sloan Kettering Cancer Center (New York, NY), Baptist Hospital of Miami (Miami, FL) and Brigham and Women’s Hospital (Boston, MA). The late-breaking podium presentation was given by Francois Cornelis, M.D., PhD, Director of the Neuro Vascular Interventional Radiology Program at Memorial Sloan Kettering Cancer Center.

REMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting

Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter
BRAINTREE, Mass., April 01, 2025 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, is providing this reminder that data from the Company’s ACCESS-PVI trial will be presented by Francois Cornelis, MD, PhD, FCIRSE, Memorial Sloan Kettering Cancer Center, Department of Radiology. This is the first time data from the study will be presented via a podium presentation, to take place on Wednesday, April 2, 11:33am CT.

Looking to stand out from the crowd during your job search? Click below to gain access to our top tips & tools for candidates during the hiring process!

Recruiting Done Differently.

Improving lives by uniting great people with great companies.

Sign up for our Monthly Newsletter

We’re committed to sharing up-to-date industry insights, our newest career opportunities, and valuable tools to support you throughout your next job search. Let’s stay connected!